12.01.05
Indication: Atopic dermatitis (AD)
Source: Archives of Disease in Childhood 2005;90:892-897.
Research: Fifty-six children, aged 6-18 months, with moderate or severe AD were recruited into a randomized double-blind, placebo-controlled trial. The children were given a probiotic (Lactobacillus fermentum) or an equivalent volume of placebo, twice daily for eight weeks. A final assessment at 16 weeks was performed.
Results: The main outcome measures were severity and extent of AD, as measured by the Severity Scoring of Atopic Dermatitis (SCORAD) index. The reduction in SCORAD index over time was significant in the probiotic group but not the placebo group. More children receiving probiotics (92%) had a SCORAD index that was
better than baseline at week 16 compared with the placebo group. At the completion of the study more children in the probiotic group had mild AD compared to the placebo group. Researchers concluded that supplementation with the probiotic L. fermentum is beneficial in improving the extent and severity of AD in young children with moderate or severe disease.
Source: Archives of Disease in Childhood 2005;90:892-897.
Research: Fifty-six children, aged 6-18 months, with moderate or severe AD were recruited into a randomized double-blind, placebo-controlled trial. The children were given a probiotic (Lactobacillus fermentum) or an equivalent volume of placebo, twice daily for eight weeks. A final assessment at 16 weeks was performed.
Results: The main outcome measures were severity and extent of AD, as measured by the Severity Scoring of Atopic Dermatitis (SCORAD) index. The reduction in SCORAD index over time was significant in the probiotic group but not the placebo group. More children receiving probiotics (92%) had a SCORAD index that was
better than baseline at week 16 compared with the placebo group. At the completion of the study more children in the probiotic group had mild AD compared to the placebo group. Researchers concluded that supplementation with the probiotic L. fermentum is beneficial in improving the extent and severity of AD in young children with moderate or severe disease.